Open‐label trial of ranolazine for the treatment of paramyotonia congenita

ABSTRACTIntroductionParamyotonia congenita (PMC) is a nondystrophic myotonic disorder that is believed to be caused by a defect in Nav1.4 sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies are lacking.MethodsWe conducted an open‐label, single‐center trial of ranolazine to evaluate efficacy and tolerability in patients with PMC. Subjective symptoms of stiffness, weakness, and pain as well as clinical and electrical myotonia were evaluated. Baseline measures were compared with those after 4 weeks of treatment with ranolazine.ResultsRanolazine was tolerated well without any serious adverse events. Both subjective symptoms and clinical myotonia were significantly improved. Duration of myotonia was reduced according to electromyography, but this change was not statistically significant in all tested muscles.DiscussionOur findings support the use of ranolazine as a treatment for myotonia in PMC and suggest that a randomized, placebo‐controlled trial is warranted. Muscle Nerve 59:240–243, 2019